Lisdexamfetamine Dimesylate

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

Also Known As:

Networked: 332 relevant articles (62 outcomes, 116 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Adeyi, Ben: 22 articles (12/2017 - 12/2010)
2.	Dirks, Bryan: 20 articles (12/2017 - 12/2010)
3.	Gasior, Maria: 19 articles (06/2018 - 06/2010)
4.	McElroy, Susan L: 16 articles (01/2022 - 01/2015)
5.	Childress, Ann C: 15 articles (12/2022 - 07/2008)
6.	Findling, Robert L: 15 articles (12/2022 - 03/2007)
7.	Babcock, Thomas: 15 articles (01/2017 - 12/2010)
8.	Scheckner, Brian: 15 articles (01/2017 - 12/2010)
9.	Adler, Lenard A: 13 articles (01/2021 - 09/2008)
10.	Banaschewski, Tobias: 13 articles (01/2020 - 09/2013)

Related Diseases

1.	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 04/01/2016 - "This approval reflects the results of three short-term trials in adults with ADHD in which fixed- or flexible-dose lisdexamfetamine produced significantly greater improvements than placebo in ADHD symptoms, overall functioning, executive functioning (including in patients with significant pre-existing impairment) and quality of life. " 07/01/2013 - "The primary objective of this study was to evaluate the efficacy of lisdexamfetamine dimesylate for executive function deficits in adults with ADHD and clinically significant executive function impairment using self-reported Behavior Rating Inventory of Executive Function-Adult version (BRIEF-A) assessments. " 11/15/2009 - "Clinical trials in children age 6-12 years and adults with ADHD have shown lisdexamfetamine to be safe and effective, with significant improvement of ADHD-related rating scores. " 09/01/2013 - "This post hoc analysis showed that, at the doses tested, patients treated with lisdexamfetamine showed statistically significantly greater improvement in symptoms of ADHD than those receiving OROS-MPH, as assessed using the ADHD-RS-IV and CGI-I. The safety profiles of lisdexamfetamine and OROS-MPH were consistent with the known effects of stimulant medications." 09/01/2008 - "All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week. "
2.	Binge-Eating Disorder (Binge Eating Disorder) 10/01/2022 - "Lisdexamfetamine dimesylate (LDX) is the only drug currently approved by the FDA for the treatment of Binge-Eating Disorder (BED), but little is known about the behavioural mechanisms that underpin the efficacy of LDX in treating BED. " 04/01/2015 - "Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?" 01/01/2017 - "Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial." 01/01/2021 - "This study examined Sheehan Disability Scale (SDS) performance in binge eating disorder (BED) and explored relationships between SDS and BED outcomes using data from three placebo-controlled lisdexamfetamine (LDX) studies (two short-term, dose-optimized studies and one double-blind, randomized-withdrawal study) in adults with Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR)-defined BED. " 01/01/2021 - "Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale."
3.	Bulimia (Binge Eating) 11/01/2017 - "Its approval was based on the results of two pivotal short-term (12 weeks) phase III studies, which showed a significantly greater reduction in binge eating days/week at the end of the study with lisdexamfetamine 50-70 mg/day than with placebo. " 01/01/2016 - "Meta-analysis of data pooled from three acute RCTs significantly favored lisdexamfetamine over placebo in the reduction of binge eating days/week, Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score, weight, response, and remission rates (all, P≤0.01). " 09/20/2016 - "Lisdexamfetamine (mean difference [MD], -6.50 [CI, -8.82 to -4.18]) and SGAs (MD, -3.84 [CI, -6.55 to -1.13]) reduced binge-eating-related obsessions and compulsions, and SGAs reduced symptoms of depression (MD, -1.97 [CI, -3.67 to -0.28]). " 10/01/2022 - "The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms: an experimental medicine study." 01/01/2018 - "However, IPT, SSRI, and lisdexamfetamine received only modest support in terms of cessation of or reduction in the frequency of binge eating. "
4.	Bulimia Nervosa 01/01/2021 - "This study examined the feasibility, safety, and potential efficacy of lisdexamfetamine (LDX) as a treatment for adults with bulimia nervosa (BN). " 11/16/2023 - "Correction: Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa." 05/22/2023 - "There is emerging evidence that stimulants warrant further investigation as a treatment for bulimia nervosa (BN) including a recent open-label feasibility trial examining the use of lisdexamfetamine dimestylate (LDX) for BN. " 05/22/2023 - "Secondary outcomes and qualitative findings of an open-label feasibility trial of lisdexamfetamine dimesylate for adults with bulimia nervosa." 01/01/2021 - "A feasibility study evaluating lisdexamfetamine dimesylate for the treatment of adults with bulimia nervosa."
5.	Feeding and Eating Disorders (Eating Disorder) 05/22/2023 - "Participants in this study took lisdexamfetamine dimesylate (LDX) for 8 weeks while their eating disorder symptoms and medical status were carefully monitored. " 09/01/2023 - "Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. " 01/01/2022 - "Lisdexamfetamine for binge eating disorder (4 RCTs; n = 900) was associated with larger reductions in eating disorder symptom severity on the Yale-Brown Obsessive Compulsive Scale modified for binge eating (YBOCS-BE) than placebo (pooled mean difference, -5.75 [95% CI, -8.32 to -3.17]). " 01/01/2022 - "No treatment trials enrolled screen-detected populations; guided self-help, lisdexamfetamine, and topiramate were effective for reducing eating disorder symptom severity among referred populations with binge eating disorder, but pharmacotherapies were also associated with harms." 03/01/2023 - "At the moment, the recommended psychotropic medication for eating disorders is represented by fluoxetine for bulimia nervosa and lisdexamfetamine for binge eating disorder."

Related Drugs and Biologics

1.	Prodrugs
2.	Amphetamine (Amfetamine)
3.	Lisdexamfetamine Dimesylate
4.	Methylphenidate (Ritalin)
5.	Dextroamphetamine (Dexedrine)
6.	Atomoxetine Hydrochloride (Strattera)
7.	Salts
8.	Modafinil (Provigil)
9.	Amphetamines
10.	Antidepressive Agents (Antidepressants)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Nicotine Replacement Therapy
4.	Aftercare (After-Treatment)
5.	Stents